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Summary We studied 51 paired samples of tissue sections and cytosol extracts from patients with breast
cancer. A very high affinity monoclonal antibody to human p53 protein, DO-I, and polyclonal serum CM-1 to
p53 protein were used for two site ELISA assays and CM-1 was used for immunohistochemistry to detect p53
protein accumulation in breast cancer samples. Eighteen carcinomas were positive for p53 by tissue staining
and ELISA assay. Nineteen tumours were negative by ELISA and immunohistochemistry, and 14 cases with
low levels of positive staining by immunohistochemistry were negative by the ELISA assay. A statistically
significant correlation has been found between the degree of staining and the amount of p53 protein measured
by ELISA (Pearson's correlation coefficient r=0.59, P<0.00001).
Our ELISA assay offers an alternative approach to evaluating the p53 status of breast biopsy material, using
cytosol extracts routinely prepared for steroid hormone receptor assays. This assay should also be of general
application to other situations where the level of p53 protein needs to be determined.
Mutations of the tumour-suppressor gene p53 have been
reported to be a frequent feature of carcinomas of the breast
(Bartek et al., 1990; Nigro et al., 1989), lung (Chiba et al.,
1990; Iggo et al., 1990; Nigro et al., 1989; Takahashi et al.,
1989) and colon (Baker et al., 1989; Nigro et al., 1989;
Rodrigues et al., 1990) and also ofcertain types of leukaemia
(Ahuja et al., 1989). These mutations are often missense
mutations and accompany the loss of the wild-type allele on
chromosome 17p, where the p53 gene is located.
Missense mutations in the p53 gene can result in the
production of abnormal protein with novel oncogenic pro-
perties and a prolonged half-life (Lane & Benchimol, 1990;
Levine et al., 1991) thereby leading to its accumulation in
tumour cells (Baker et al., 1989; Bartek et al., 1990; Iggo et
al., 1990; Nigro et al., 1989; Rodrigues et al., 1990; Taka-
hashi et al., 1989). Since the p53 protein does not usually
accumulate in normal cells and is in effect undetectable by
immunohistochemical and immunochemical techniques, the
accumulation of p53 appears to be a potential novel marker
for malignancy (Hall et al., 1991) and in certain tumour types
is associated with poor prognosis (Cattoretti et al., 1988;
Thor et al., 1992).
A particular goal of breast cancer research has been the
identification of tumour-associated markers which predict
unfavourable prognosis and are independent of lymph node
status and other prognostic factors (Callahan, 1992). The
accumulation of p53 protein has the potential to be one such
marker in breast cancer (Thor et al., 1992). The accumulation
of p53 can be detected by immunohistochemical methods in
frozen and routinely prepared clinical material, however,
results in fixed material are dependent upon the type of
fixative and the conditions of fixation. For p53 accumulation
to be a diagnostic marker of value it is important to standar-
dise the analysis method in relation to pre-existing proce-
dures and reagents.
In this study we describe a two-site ELISA assay (Midgley
et al., 1992; Vojtesek et al., 1992) to determine the levels of
p53 protein in cytosol extracts routinely prepared in many
hospitals for steroid hormone receptor assays using well
characterised and commercially available reagents. We have
compared results from this method with immunohistochem-
ical analysis in routinely prepared tissue sections.
Materials and methods
Tumour tissue
Tumour tissue was excised from patients with primary mam-
mary carcinoma attending the ICRF Clinical Oncology Unit
at Guy's Hospital. Histological classification and grading was
carried out by members of the histopathology department;
p53 immunoreactivity was reviewed by CJF.
Preparation ofcytosol
Samples of primary breast carcinoma tissue were obtained at
the time of surgery. The samples were freed from surround-
ing fat and connective tissue, cut to convenient size (approx-
imately 250 mg) and placed immediately in vials in liquid
nitrogen. Samples were stored at - 70°C until required.
Homogenisation of the frozen sample was carried out using a
microdismembrator (Braun, Melsungen, Germany).
The frozen powder was transferred to a beaker and sus-
pended in 10 mM Tris buffer, pH 7.4, containing 1.5 mM
EDTA, 5.0 mM sodium molybdate and 1.0 mM monothiogly-
cerol, and a soluble extract prepared according to the instruc-
tions in the Abbott ER EIA kit for measuring oestrogen
receptors. The protein concentrations of the cytosol extracts
were determined by a dye binding assay (Bradford, 1976). It
is standard practice in our laboratory to fix and process a
piece of tissue adjacent to that selected for the receptor and
p53 assays. This histology control section ensures that the
sample is representative of the tumour as a whole and con-
tains sufficient tumour tissue to ensure a valid assay.
Immunohistochemistry
Excised tumour tissue was fixed in phenol formalin (2%
phenol in formol saline, (Hopwood et al., 1989)) and embed-
ded in paraffin wax. Three tLm sections were cut and stained
with the anti-p53 polyclonal antibody CM1 (Midgley et al.,
1992) using a peroxidase conjugated streptavidin biotin tech-
nique, as described by Midgley et al. (Midgley et al., 1992).
The use of phenol formalin fixations is particularly good for
preserving the antigenicity of nuclear proteins, such as p53
(Midgley et al., 1992).
Scoring system
Staining was assessed in two ways. Firstly the intensity of
staining was given a score between 1-3, depending on wheth-
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Figure 1 Immunohistochemical staining with anti-p53 antibody CM-I in infiltrating ductal mammary carcinomas using a
peroxidase conjugated streptavidin biotin technique. Strong (a, case No. 1) and weaker (b, case No. 2) positive staining for p53
protein in the majority of nuclei in a poorly differentiated grade III infiltrating ductal carcinoma; (magnification x 400). Negative
staining c, for p53 protein in a moderately differentiated grade II infiltrating ductal carcinoma (magnification x 400).1256 B. VOJTtgEK et al.
er the staining was weak, moderate or strong. Secondly the
proportion of malignant cells staining was accorded a score
between 1-4, with 1 representing less than 25% of tumour
cells staining postively; 2 with 25-50% positive cells; 3 with
50-75% positive cells and 4 with greater than 75% positive
cells. The two scores were added together giving a range of
values of between 0-7. In addition the cellularity of the
tumour was assessed by evaluating the proportion of malig-
nant cells in the section and expressing this as a percentage.
Cellularity in the histology control tissue section was also
checked to ensure that this was similar. A total score was
then assigned to each tumour; this comprised the staining
value multiplied by the percentage cellularity.
Examples of immunohistochemical staining with anti-p53
in infiltrating ductal carcinomas are shown in Figure 1.
ELISA assay
A sandwich immunoassay to measure the level ofp53 protein
in cytosol extracts was performed using monoclonal anti-p53
antibody DO-1 (Vojtesek et al., 1992) as the solid phase
reagent and polyclonal rabbit antiserum, CM-1 (Midgley et
al., 1992) to p53, to detect the captured proteins. Falcon 96
well microtitre plates were incubated overnight at room
temperature in humid chamber with 50 tl per well of ascites
fluid of DO-I antibody (diluted 1:500) or 30 pg ml' pure
DO-I antibody, rinsed in PBS and blocked for 2 h in 3%
bovine serum albumin (BSA) in PBS (room temperature,
humid chamber).
Cytosol extracts were prepared as above. Fifty fl of a
duplicate series of ten serial twofold dilutions of each cytosol
extract in lysis buffer (I50 mM NaCl, 50 mM Tris pH 7.4,
5 mM EDTA, 1% NP40, 1 mM polymethanesulphonyl fluor-
ide) were added to the antibody coated wells and incubated
for 3 h at 4°C. The plates were washed once in PBS, twice in
0.1% NP40 in PBS and once in PBS. Rabbit antiserum
CM-I (diluted 1:1000 in 1% BSA in PBS) was then added
and incubated for 2 h at 4°C. The plates were washed as
above and peroxidase-conjugated swine antiserum to rabbit
immunoglobulin (Dako, Glostrup, Denmark, diluted 1:1000
either in 5% foetal calf serum in PBS or in 1% BSA in PBS)
was added for 2 h, incubated at 4°C and bound enzyme
activity detected visually with tetramethylbenzidine and the
results monitored in an automatic ELISA plate reader (Har-
low & Lane, 1988). The assay was standardised using pure
soluble recombinant p53 isolated from bacteria (Midgley et
al., 1992). The equation of the standard curve (Figure 2) was
solved by virtue of a curve fitting programme (Cricket
Graph, Cricket Soft Ware Inc, Malvern, PA 19355, USA)
and used to determine ng's of p53 per o.d. unit. From this
conversion the concentration of p53 (ng of p53 per mg of
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Figure 2 Two site immunoassay using known concentrations of
soluble recombinant human p53 protein. Microtitre plates were
coated with anti-p53 monoclonal antibody DO-1 and after incu-
bation with soluble recombinant human p53 probed with anti-
p53 polyclonal rabbit serum CM-1.
protein) in the cytosol samples was calculated using the
highest point from the linear range of the serial dilution series.
Results
The staining and ELISA results of 51 paired samples of
tissue sections and cytosol extracts were compared (Table I).
The positive immunohistochemical scores ranged from 30-
350 arbitrary units while the ELISA scores ranged from
2-230 ng of p53 protein per mg ofcytosol protein (Table II).
There was a highly significant correlation between staining
and the amount of p53 protein in the ELISA assay (Pear-
son's correlation coefficient r = 0.59, P<0.00001). Of the 51
cases examined eighteen had detectable levels of p53 in the
ELISA assay and all showed clear positive staining for p53
with total staining score of 90 or above (Table I category A;
Figures la and b and Figure 3). The remaining 33 tumours
were all negative by the ELISA assay. Eleven of these were
totally negative by immunohistochemistry (Table I category
B; Figure lc) and eight (Table I category C) showed only
very rare positive malignant cells (less than 1% of the malig-
nant cells examined) and it is highly unlikely that any of
these tumours would actually be found to be positive by the
ELISA assay. This leaves a final group of 14 tumours (Table
I category D) which were negative by ELISA but showed
some positive staining by immunohistochemistry. The stain-
ing in these tumours was of low intensity and present in
fewer than 50% of the tumour cells. In all but one case the
cellularity of the tumour was also low with less than one
third of the tissue consisting of malignant cells, giving scores
all below 100. The one section with a slightly higher cel-
lularity had a score of 160, and this might have been ex-
pected to be positive in the ELISA assay. Re-examination of
this case showed that the cellularity of the cytosol sample
used was less than that used for immunohistochemical pre-
paration and the resulting cytosol protein concentration was
only 0.3 mg ml-'. This appears to be outside the range of
sensitivity of the assay since experience has shown that it is
preferable to have a cytosol protein concentration of at least
0.6 mg ml-' but the preferred concentration is 1 mg ml- . To
verify the reproducibility of this type of ELISA assay, and to
assess its use for routine clinical measurement of p53 protein
in cytosol extracts, we have carried out many comparative
studies with this assay on protein extracts from different
human tumour cell lines (with known high and low level of
p53 protein and without p53 protein too; Figures 4a and b).
The results suggest that the assay is highly reproducible.
Discussion
There is increasing interest in the relationship between the
presence of abnormal amounts of p53 protein in mammary
carcinoma and the clinical outcome of the patients. Our own
data (Barnes et al., 1993) and work by others (Thor et al.,
1992) indicate that the presence of the protein is strongly
associated with a short disease free interval and overall sur-
vival in node negative as well as node positive patients.
Table I Comparison of p53 expression in 51 cases of breast cancer
by ELISA and immunohistochemistry (IHC)
Number of
Category IHC0 ELISAb cases %
A +++ + 18 -35%
B 11 -21%
C + - 8 16%
D + 14 -27%
aStaining patterns: -= no detectable staining; +/-= less than
1% of the cells stained strongly positive; + = weaker staining with
less than 50% malignant cells stained positive; + + + = strong
staining with majority of malignant cells stained positive. bReactivity
of ELISA: + = reactivity; -= no reactivity.
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Table II Quantitative comparison of p53 expression in 18 cases of breast cancer
Total p53 (ngmg-'
Score cytosol protein)
Case No Intensity Proportion Value % IHC ELISA
1 3 4 7 50 350 146
2 3 2 5 30 150 12
3 2 2 4 60 240 11
4 3 4 7 50 350 17
5 3 4 7 50 350 118
6 3 4 7 30 210 5
7 2 3 5 50 250 29
8 3 3 6 20 120 4
9 3 3 6 30 180 16
10 2 2 4 40 160 11
11 3 4 7 40 280 10
12 1 2 3 50 150 5
13 1 2 3 30 90 2
14 2 3 5 20 100 2
15 3 4 7 40 280 123
16 3 3 6 30 180 2
17 3 4 7 30 350 230
18 3 4 7 30 210 45
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Figure 3 ELISA assay to quantitate p53 levels in cytosol ex-
tracts from primary breast tumours. Microtitre plates were coated
with anti p53 monoclonal antibody DO-1 and then incubated
with a range of concentrations of a cytosol extract. Bound p53
protein was quantitated using the polyclonal rabbit anti-p53
antibody CM-1 and a peroxidase-coupled anti-rabbit immuno-
globulin. Typical result with various levels of p53 protein from
different cytosol extracts are shown: case No. 1 (-O-) and case
No. 2 (-* ).
Currently, there are numerous pilot studies on potential
prognostic markers. An essential requirement for which is
that the procedure for the assessment of a marker should be
easy to perform and reproducible in a variety of laboratories.
The development of the ELISA assay described in this paper
fulfils this requirement and could facilitate definitive studies
on the role of p53 in prognosis.
General molecular biology techniques involving the study
of DNA using Southern blotting, polymerase chain reaction
and direct DNA sequencing are not easily performed in
clinical laboratories. An alternative method for detecting
genetic abnormalities is the study of expression of the pro-
tein. While antibodies are available which can demonstrate
the presence of p53 protein in routine archival blocks (Midg-
ley et al., 1992; Vojtesek et al., 1992) these techniques are
generally restricted to use in histopathology laboratories.
Moreover, even when the same antibody is used there have
been considerable differences in the interpretations of stain-
ing, in particular the degree of staining and the assessment of
positivity (Cattoretti et al., 1988; Davidoff et al., 1992; Os-
trowski et al., 1991; Thor et al., 1992) for comparable
immunohistochemical studies.
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igure 4 Two site immunoassay using: a, b, the same range of
concentrations of independently prepared cell extracts from the
same cell line. a, T47D cell extract (prep No. 1 -0-; prep
No. 2 *-); b, MCF7 cell extract (prep No. 1 0 ; prep
No. 2 * ). Microtitre plates were coated with anti-p53 mon-
oclonal antibody DO-1 and probed with anti-p53 polyclonal
rabbit serum CM-1.
The ELISA assay we described here can be carried out on
the cytosol extracts routinely prepared for the steroid hor-
mone receptor assay. This means that the assay can be easily
carried out in laboratories which already measure steroid
hormone receptors. Whilst some structural forms of the p53
protein are heat-labile, the stringent collection procedures
- in
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necessary for the receptor assay are also ideal for preserving
the p53 protein for the ELISA assay. In this study we have
shown that the ELISA assay is not quite as sensitive as the
immunohistochemical technique, but this should not be a
practical problem as our own preliminary data on prognosis
(Barnes et al., 1993) has shown that it is the carcinomas in
which more than 75% of the cells express the protein (Table
I category A and Table II) which are associated with poor
prognosis. This may have a simple genetic basis as it is these
high levels of p53 that have generally shown a clear correla-
tion with the expression of mutant p53 (Bartek et al., 1990;
Davidoff et al., 1991a; Davidoff et al., 1991b) while low level
expression of p53 may result from other processes such as
DNA damage (Lu et al., 1992). In in vitro systems high levels
of mutant p53 are required for cellular transformation (Zam-
betti et al., 1992). In the present study discrepancies between
the two methods only occurred when fewer than 50% of the
tumour cells expressed the protein.
It is inevitable that some discrepancy would be found
between the results of the two assays since they were carried
out on different pieces of tumour material. The immunohis-
tochemical procedure was carried out on tumour tissue taken
for diagnostic purposes. The ELISA assay was carried out on
material selected for the receptor assay. In an attempt to
ensure that the two pieces of tissue were similar, comparisons
were made between the cellularity of tumour in the tissue
selected for immunohistochemistry and that used in the
ELISA assay. In all but one case the cellularity values were
similar. The exception had a IHC score of 160 and a basal or
zero ELISA value.
The ELISA assay of p53 in cytosols with these two new
antibodies is much more sensitive than the previously avail-
able ELISA assays, which used monoclonal antibodies with
lower affinity for the p53 protein or which specifically recog-
nised a particular conformation of the p53 protein. Our
monoclonal antibody DO-1 which we are using as a solid
phase in the ELISA assay, is specific for a denaturation-
resistant epitope at the N-terminus (Vojtesek et al., 1992) and
has a very high affinity for the p53 protein. While this paper
has specifically examined the accumulation of p53 in breast
biopsies, it is equally applicable to other tissues or cell lines
and should be of widespread application for determining the
levels of p53 protein. Since our assay uses commercially
available antibodies (DO-1 is available from DAKO and
Oncogene Sciences and CM1 is available from Nova Castra,
Newcastle), and gives a simple quantitative result from nor-
mal cytosol preparations, it should be of wide application in
determining if p53 levels can provide a basis for selecting
patients that might benefit from different treatment protocols
(Callahan, 1992; McGuire, 1991).
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